Physicians' Academy for Cardiovascular Education

SGLT-2 inhibitor did not decrease risk of stroke in diabetic patients

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Literature - Zinman B, Inzucchi SE, Lachin, ScD JM, et al. - Stroke. 2017;48: published online ahead of print

Main results

Conclusion

In T2DM patients at high cardiovascular risk enrolled in the EMPA-REG OUTCOME trial, empagliflozin, when compared with placebo, was not associated with either a reduction or an increase in the risk of cerebrovascular events.

References

Show references

Find this article online at Stroke

Share this page with your colleagues and friends: